Hims & Hers Health falls after bigger-than-expected Q2 loss
BUZZ-Hims & Hers Health falls after bigger-than-expected Q2 loss ** Shares of telehealth firm Hims & Hers Health HIMS.N down 7.15% at $29.5 in premarket trading
** Co posted a bigger-than-expected Q2 loss on Monday, driven by higher costs tied to its shift to branded weight-loss drugs
** Co's growth in its GLP-1 weight-loss business and international expansion boosted subscriptions, but weighed on margins
** Analysts at Leerink Partners say HIMS growth is likely to continue with expected launch of peptide products, but a difficult balance between spending and growth limits its optimism
** HIMS reported a Q2 net loss of 37 cents per share, compared with analyst's estimate of a 1-cent loss per share
** Sixteen analysts rate stock "hold" on average; median PT $30.5 - data compiled by LSEG
** As of last day's close, stock down 2.15% YTD
(Reporting by Kanishka Ajmera in Bengaluru)
((mail to: Kanishka.Ajmera@thomsonreuters.com))
Recent news on Hims & Hers Health
See all newsBrief: Hims & Hers Health Expands Testosterone Care With Injectable And Oral TRT
Hims & Hers Health launches online weight management service for men in Germany
Corrected: US FDA takes step to change peptide compounding policy (Oct 15)
Brief: Hims & Hers Names Jon Franklin As Chief Accounting Officer
Brief: Hims & Hers Names Chief Medical Officers In The Uk And Australia, Deepening Its Investment In Local Clinical Leadership